Showing results (1571-1580 of 5,501) with videos related to
Sort By:
Pageof 551
Inflammatory Bowel Diseases|February 3, 2011
Development and validation of the Crohn's disease perceived work disability questionnaireMercedes Vergara, Antonia Montserrat, Francesc Casellas, et al.Inflammatory Bowel Diseases|February 3, 2011
Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: a population-based studyValérie Crombé, Julia Salleron, Guillaume Savoye, et al.Inflammatory Bowel Diseases|February 3, 2011
Thrombin generation in pediatric patients with Crohn's diseaseHeike Bernhard, Andrea Deutschmann, Bettina Leschnik, et al.Inflammatory Bowel Diseases|February 22, 2011
Are NOD2 polymorphisms linked to a specific disease endophenotype of Crohn's disease?Stina Rikke Jensen, Ole Haagen Nielsen, Susanne BrixInflammatory Bowel Diseases|February 22, 2011
Inadequate knowledge of immunization guidelines: a missed opportunity for preventing infection in immunocompromised IBD patientsJames H Yeung, Karen J Goodman, Richard N FedorakInflammatory Bowel Diseases|June 22, 2010
Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-α antibody-treated patients with inflammatory bowel diseaseFlorian Beigel, Fabian Schnitzler, Rüdiger Paul Laubender, et al.Inflammatory Bowel Diseases|July 15, 2010
Seroreactivity against glycolytic enzymes in inflammatory bowel diseaseNathalie Vermeulen, Severine Vermeire, Ingrid Arijs, et al.Inflammatory Bowel Diseases|July 15, 2010
Characterization of immunologic defects in patients with common variable immunodeficiency (CVID) with intestinal diseaseShradha Agarwal, Paul Smereka, Noam Harpaz, et al.Inflammatory Bowel Diseases|July 15, 2010
Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agentSreedhar Subramanian, Vijay Yajnik, Bruce E Sands, et al.Inflammatory Bowel Diseases|July 21, 2010
Presentation and outcome of histoplasmosis in pediatric inflammatory bowel disease patients treated with antitumor necrosis factor alpha therapy: a case seriesJennifer L Dotson, Wallace Crandall, Hayat Mousa, et al.Pageof 551